Incyte Corp. (INCY)
127.99
+0.18
(+0.14%)
USD |
NASDAQ |
Aug 24, 16:00
127.99
0.00 (0.00%)
After-Hours: 20:00
Incyte Net Income (Quarterly) : 585.60M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 585.60M |
| March 31, 2026 | 303.33M |
| December 31, 2025 | 299.28M |
| September 30, 2025 | 424.17M |
| June 30, 2025 | 405.00M |
| March 31, 2025 | 158.20M |
| December 31, 2024 | 201.21M |
| September 30, 2024 | 106.46M |
| June 30, 2024 | -444.60M |
| March 31, 2024 | 169.55M |
| December 31, 2023 | 201.08M |
| September 30, 2023 | 171.27M |
| June 30, 2023 | 203.55M |
| March 31, 2023 | 21.70M |
| December 31, 2022 | 28.46M |
| September 30, 2022 | 112.78M |
| June 30, 2022 | 161.43M |
| March 31, 2022 | 37.99M |
| December 31, 2021 | 563.85M |
| September 30, 2021 | 181.74M |
| June 30, 2021 | 149.46M |
| March 31, 2021 | 53.54M |
| December 31, 2020 | 149.85M |
| September 30, 2020 | -15.20M |
| June 30, 2020 | 290.30M |
| Date | Value |
|---|---|
| March 31, 2020 | -720.64M |
| December 31, 2019 | 111.00M |
| September 30, 2019 | 128.27M |
| June 30, 2019 | 105.32M |
| March 31, 2019 | 102.31M |
| December 31, 2018 | 69.06M |
| September 30, 2018 | 29.18M |
| June 30, 2018 | 52.39M |
| March 31, 2018 | -41.14M |
| December 31, 2017 | -149.63M |
| September 30, 2017 | 36.05M |
| June 30, 2017 | -12.48M |
| March 31, 2017 | -187.08M |
| December 31, 2016 | 8.873M |
| September 30, 2016 | 36.88M |
| June 30, 2016 | 34.42M |
| March 31, 2016 | 24.05M |
| December 31, 2015 | 55.18M |
| September 30, 2015 | -39.58M |
| June 30, 2015 | 9.294M |
| March 31, 2015 | -18.36M |
| December 31, 2014 | -36.94M |
| September 30, 2014 | 59.29M |
| June 30, 2014 | -36.87M |
| March 31, 2014 | -33.96M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -67.23M |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| BioMarin Pharmaceutical, Inc. | 44.76M |
| Eli Lilly & Co. | 7.095B |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.674B |
| Total Expenses (Quarterly) | 1.088B |
| EPS Diluted (Quarterly) | 2.812 |
| Enterprise Value | 21.19B |
| Gross Profit Margin (Quarterly) | 92.57% |
| Profit Margin (Quarterly) | 34.98% |
| Earnings Yield | 6.13% |
| Operating Earnings Yield | 7.00% |
| Normalized Earnings Yield | 6.227 |